Empery Asset Management Acquires 6.6M X4 Pharmaceuticals Shares, Boosting Portfolio

Empery Asset Management has acquired 6,545,732 shares of X4 Pharmaceuticals at $4 per share, marking a significant addition to its portfolio. The firm primarily invests in the healthcare and consumer cyclical sectors, reflecting its strategic focus on industries with significant growth potential. X4 Pharmaceuticals is a biopharmaceutical company developing novel therapeutics for rare immune system diseases. The acquisition positions X4 Pharmaceuticals as a significant component of Empery Asset Management's portfolio, accounting for 9.99% of its total holdings.